QUESTIONS
Ipamorelin FAQ
Direct, cited answers to the questions people actually ask about ipamorelin — kinetics, effects, safety, and the combination protocols.
How to reconstitute CJC-1295 ipamorelin 5mg?
This digest gives no reconstitution recipe. In the research-supply context, ipamorelin is a lyophilized powder reconstituted with bacteriostatic water and kept refrigerated, as a general peptide-handling note — not a clinical instruction [2]. The only documented human administration was intravenous and clinician-supervised, and no human dose, volume, or protocol is provided here [2].
How long does ipamorelin stay in your system?
The terminal half-life in humans is about 2 hours, so the molecule is largely cleared within roughly ten hours (about five half-lives), with clearance 0.078 L/h/kg [1]. The growth-hormone pulse it triggers is briefer still, peaking near 40 minutes [1]. Anti-doping urine detection follows a separate clock set by assay sensitivity, not by plasma half-life.
How long does it take for ipamorelin to work?
The growth-hormone pulse peaks about 40 minutes after an IV dose — that is the measured pharmacologic onset [1]. The subjective effects people report, such as deeper sleep, emerge over one to two weeks and are anecdotal, not clinical [1]. The one completed human efficacy trial, for postoperative ileus, did not meet its endpoint [2].
What is the half-life of ipamorelin?
Approximately 2 hours, measured as the terminal half-life in healthy male volunteers given IV doses of 4.21–140.45 nmol/kg [1]. Accompanying parameters were clearance 0.078 L/h/kg and steady-state volume of distribution 0.22 L/kg, with dose-proportional kinetics [1]. In rats, plasma clearance is roughly five-fold lower than GHRP-6 [1].
Is ipamorelin available in an oral form?
Not effectively. Ipamorelin itself is not orally bioavailable [10]. Oral activity exists only for engineered analogs designed from ipamorelin, such as NN703, which showed about 30% oral bioavailability and a 4.1-hour half-life in dogs [10]. The human and clinical data for ipamorelin are intravenous [1][2].
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and a selective growth hormone secretagogue — it activates the ghrelin receptor (GHS-R1a) on the pituitary to release growth hormone [3]. Its defining trait is selectivity: potent GH release without meaningfully raising cortisol or prolactin, even far above its GH ED50 [3]. It is not an approved drug [2].
What does ipamorelin do for you?
In studies, ipamorelin triggers a single growth-hormone pulse via the ghrelin receptor, selectively and without raising cortisol or prolactin [3]. People in research-use communities report deeper sleep and faster recovery, but those are anecdotal, not clinical findings [1]. Its one completed human efficacy trial, for bowel recovery, did not meet its endpoint [2].
What is ipamorelin peptide?
Ipamorelin peptide is a wholly synthetic five-amino-acid chain that mimics the hunger hormone ghrelin at the GHS-R1a receptor to release growth hormone [3]. Non-natural residues (Aib at position 1, plus D-amino acids) make it resistant to rapid enzymatic breakdown [3]. It carries the code NNC 26-0161 and was discovered at Novo Nordisk [3].
What are the risks of ipamorelin?
Documented gaps dominate: no Phase 3 trial and no long-term human safety data, with the only completed RCT missing its endpoint [2]. A class-level concern is a 28-day rat study of a related GHS-R1a agonist that found dose-dependent myocardial degeneration [6]. GH-axis stimulation also raises theoretical IGF-1 and glucose concerns [3].
Does ipamorelin reduce belly fat?
No controlled human trial shows ipamorelin reduces belly fat. The most recent in-vivo study, in ferrets, found ipamorelin inhibited chemotherapy-induced weight loss by about 24% — a weight-protective, not fat-reducing, effect [5]. Community reports of a gradually leaner build are anecdotal and confounded by diet and training [1].
What are the downsides of ipamorelin?
The biggest downside is unproven benefit: the one completed human trial missed its endpoint and no indication is approved [2]. Reported side effects — flushing, increased appetite, mild water retention, injection-site irritation — are anecdotal [1]. A class-level cardiovascular signal from a related agonist and unverified research-grade purity round out the concerns [6].
Why is ipamorelin being discontinued?
Ipamorelin was never an approved drug to discontinue; its clinical program effectively stopped after the Phase 2 ileus trial missed its primary endpoint, with no Phase 3 to follow [2]. Separately, in 2024 the FDA removed ipamorelin acetate from Category 2 of the interim 503A bulk-substances list, restricting compounding-pharmacy access [2].
What does CJC-1295 and ipamorelin do?
Together they engage two complementary pathways: CJC-1295 (a GHRH analog) raises GH-releasing drive while ipamorelin (a GHS-R1a secretagogue) adds a selective GH pulse [3]. Class-level human data show GHRH-plus-secretagogue co-administration produces synergistic GH release [13]. The specific combination has no controlled trial for any wellness outcome [2].
Does ipamorelin increase IGF-1?
Not consistently in short studies. In adult rats, 15 days of subcutaneous ipamorelin increased bone growth with no measurable change in total IGF-1 [4]. In diabetic mice, ipamorelin raised GH but IGF-1 was suppressed amid GH-receptor resistance [8]. Sustained GH elevation can raise IGF-1, but short ipamorelin exposure often does not [4].
How does CJC-1295 ipamorelin work?
Ipamorelin activates GHS-R1a (the ghrelin receptor) on pituitary cells via a calcium pathway, while CJC-1295 activates the GHRH receptor via a cAMP pathway — distinct mechanisms that combine for greater GH release [3]. Class-level work shows the GHRP-plus-GHRH combination becomes synergistic, partly by overcoming somatostatin braking [13][14].
How much CJC-1295 ipamorelin should I take?
This digest provides no dose. No controlled human trial of the combination establishes a dose for any outcome [2]. Community stack protocols have no peer-reviewed human dosing basis and are described as anecdotal, not recommended [2]. The supporting evidence is mechanistic class-level synergy, not a personal dose [13].
Does CJC-1295 ipamorelin work?
Mechanistically, GHRH-analog-plus-secretagogue co-administration raises GH synergistically in humans at the class level [13]. But no controlled trial tests the specific CJC-1295 + ipamorelin combination for fat loss, muscle, sleep, or anti-aging [2]. So the GH-raising step is real; the sought-after outcomes remain unproven in any combination trial [2].
Does ipamorelin make you hungry?
It can, mechanistically. Ipamorelin acts on the ghrelin receptor — the body's hunger-signal receptor — and ghrelin-receptor agonists as a class stimulate appetite [3]. Community reports describe a noticeable uptick in hunger after injection, generally milder than with GHRP-6 [1]. This is anecdotal at the reported-experience level but consistent with the receptor mechanism [3].
Will I gain weight on ipamorelin?
No controlled human trial answers this. In a ferret model, ipamorelin protected against chemotherapy-induced weight loss, a weight-preserving effect [5]. The increased appetite some users report could raise intake, but any weight change in people is unstudied and confounded; the one completed human trial did not assess body weight as an outcome [2].
Does ipamorelin increase appetite?
Mechanistically yes — it activates the ghrelin (GHS-R1a) receptor, the same one the natural hunger hormone uses, and ghrelin-receptor agonists drive feeding as a class [3]. Community accounts report increased hunger after injection, described as milder than with older GHRP compounds [1]. There is no controlled human appetite study of ipamorelin specifically [3].
What does ipamorelin peptide do?
Ipamorelin peptide selectively releases growth hormone by activating the ghrelin receptor on pituitary cells, producing a single GH pulse without meaningfully raising cortisol or prolactin [3]. In animals it has increased longitudinal bone growth and, recently, reduced chemotherapy-driven weight loss [4][5]. Reported human-use benefits like deeper sleep are anecdotal [1].
Does ipamorelin cause water retention?
Possibly, mildly. GH excess is associated with sodium and water retention, and some community users report transient puffiness in fingers, ankles, or face during the first weeks, generally milder than with older GHRPs [3]. This is anecdotal, and the only completed human trial did not report water retention as a specific finding [2].